Landiolol (ONO1101) is a highly selective, ultra-short-acting competitive inhibitor of beta1 adrenergic receptors. Landiolol specifically blocks cardiac beta1 receptors, reducing heart rate and myocardial oxygen consumption. Landiolol inhibits TNF-alpha-induced excessive mitochondrial oxygen consumption and reactive oxygen species production in a sepsis model, alleviating renal injury. Landiolol has little effect on cardiac ion channels (such as L-type calcium current and inward rectifier potassium current) and has a weak negative inotropic effect. Landiolol can be used for perioperative tachycardia control and protection studies of sepsis-related acute kidney injury[1][2][3].
Molecular Weight:
509.59
CAS Number:
[133242-30-5]
Formula:
C25H39N3O8
Target:
Adrenergic Receptor,Calcium Channel,Potassium Channel,Reactive Oxygen Species (ROS)
Application Notes:
MCE Product type: Reference compound
* VAT and and shipping costs not included. Errors and price changes excepted
